Integrating phosphoproteomics into the clinical management of prostate cancer

Phosphoproteomic analysis of tumor samples has the potential to uncover significant insights into kinase signaling networks present in late stage prostate cancer that are complementary to genomic and transcriptomic approaches. Phosphoproteomics could potentially aid drug development in clinical tria...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Larry C., Tan, Victor M., Ganesan, Shridar, Drake, Justin M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5309189/
https://www.ncbi.nlm.nih.gov/pubmed/28197968
http://dx.doi.org/10.1186/s40169-017-0138-5
_version_ 1782507665975410688
author Cheng, Larry C.
Tan, Victor M.
Ganesan, Shridar
Drake, Justin M.
author_facet Cheng, Larry C.
Tan, Victor M.
Ganesan, Shridar
Drake, Justin M.
author_sort Cheng, Larry C.
collection PubMed
description Phosphoproteomic analysis of tumor samples has the potential to uncover significant insights into kinase signaling networks present in late stage prostate cancer that are complementary to genomic and transcriptomic approaches. Phosphoproteomics could potentially aid drug development in clinical trial design as well as provide utility for oncologists in the personalized therapeutic management of individual cancers through identifying novel biomarkers and druggable targets. Rapid advancement of targeted mass spectrometry platforms is underway to integrate phosphoproteomic technology with genomic assays to soon translate this information into the cancer clinic.
format Online
Article
Text
id pubmed-5309189
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-53091892017-02-28 Integrating phosphoproteomics into the clinical management of prostate cancer Cheng, Larry C. Tan, Victor M. Ganesan, Shridar Drake, Justin M. Clin Transl Med Commentary Phosphoproteomic analysis of tumor samples has the potential to uncover significant insights into kinase signaling networks present in late stage prostate cancer that are complementary to genomic and transcriptomic approaches. Phosphoproteomics could potentially aid drug development in clinical trial design as well as provide utility for oncologists in the personalized therapeutic management of individual cancers through identifying novel biomarkers and druggable targets. Rapid advancement of targeted mass spectrometry platforms is underway to integrate phosphoproteomic technology with genomic assays to soon translate this information into the cancer clinic. Springer Berlin Heidelberg 2017-02-14 /pmc/articles/PMC5309189/ /pubmed/28197968 http://dx.doi.org/10.1186/s40169-017-0138-5 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Commentary
Cheng, Larry C.
Tan, Victor M.
Ganesan, Shridar
Drake, Justin M.
Integrating phosphoproteomics into the clinical management of prostate cancer
title Integrating phosphoproteomics into the clinical management of prostate cancer
title_full Integrating phosphoproteomics into the clinical management of prostate cancer
title_fullStr Integrating phosphoproteomics into the clinical management of prostate cancer
title_full_unstemmed Integrating phosphoproteomics into the clinical management of prostate cancer
title_short Integrating phosphoproteomics into the clinical management of prostate cancer
title_sort integrating phosphoproteomics into the clinical management of prostate cancer
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5309189/
https://www.ncbi.nlm.nih.gov/pubmed/28197968
http://dx.doi.org/10.1186/s40169-017-0138-5
work_keys_str_mv AT chenglarryc integratingphosphoproteomicsintotheclinicalmanagementofprostatecancer
AT tanvictorm integratingphosphoproteomicsintotheclinicalmanagementofprostatecancer
AT ganesanshridar integratingphosphoproteomicsintotheclinicalmanagementofprostatecancer
AT drakejustinm integratingphosphoproteomicsintotheclinicalmanagementofprostatecancer

Ejemplares similares